Shares of Flexion Therapeutics, Inc. (NASDAQ:FLXN) have been assigned a consensus rating of “Buy” from the eleven ratings firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $98.33.

FLXN has been the subject of several analyst reports. Janney Montgomery Scott raised their price target on shares of Flexion Therapeutics to $570.00 and gave the company a “fair value” rating in a report on Tuesday, October 10th. Wells Fargo & Company set a $39.00 price target on shares of Flexion Therapeutics and gave the company a “buy” rating in a report on Friday, October 6th. Needham & Company LLC reissued a “buy” rating and issued a $36.00 price target on shares of Flexion Therapeutics in a report on Sunday, September 17th. Zacks Investment Research downgraded shares of Flexion Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. Finally, Northland Securities reissued a “buy” rating and issued a $40.00 price target on shares of Flexion Therapeutics in a report on Wednesday, October 4th.

Shares of Flexion Therapeutics (NASDAQ FLXN) traded up $0.08 during trading hours on Thursday, reaching $23.49. 951,900 shares of the company’s stock traded hands, compared to its average volume of 831,054. The company has a quick ratio of 12.93, a current ratio of 12.93 and a debt-to-equity ratio of 0.87. Flexion Therapeutics has a 1 year low of $15.96 and a 1 year high of $32.25.

In related news, insider Yamo Deniz acquired 3,000 shares of the company’s stock in a transaction dated Friday, September 1st. The stock was bought at an average cost of $24.15 per share, with a total value of $72,450.00. Following the acquisition, the insider now owns 5,000 shares of the company’s stock, valued at approximately $120,750. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Michael D. Clayman acquired 5,000 shares of the company’s stock in a transaction dated Wednesday, November 8th. The shares were bought at an average cost of $23.60 per share, with a total value of $118,000.00. Following the completion of the acquisition, the insider now directly owns 35,395 shares in the company, valued at approximately $835,322. The disclosure for this purchase can be found here. Insiders have bought a total of 13,075 shares of company stock valued at $315,698 over the last ninety days. 15.98% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp lifted its holdings in shares of Flexion Therapeutics by 27.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 2,716,189 shares of the specialty pharmaceutical company’s stock worth $54,921,000 after acquiring an additional 591,981 shares during the last quarter. Capital World Investors lifted its holdings in shares of Flexion Therapeutics by 2.0% during the 2nd quarter. Capital World Investors now owns 2,538,000 shares of the specialty pharmaceutical company’s stock worth $51,318,000 after acquiring an additional 49,000 shares during the last quarter. State Street Corp lifted its holdings in shares of Flexion Therapeutics by 66.3% during the 2nd quarter. State Street Corp now owns 1,379,202 shares of the specialty pharmaceutical company’s stock worth $27,888,000 after acquiring an additional 549,948 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Flexion Therapeutics by 5.9% during the 2nd quarter. Vanguard Group Inc. now owns 1,054,464 shares of the specialty pharmaceutical company’s stock worth $21,321,000 after acquiring an additional 59,143 shares during the last quarter. Finally, Wasatch Advisors Inc. lifted its holdings in shares of Flexion Therapeutics by 58.7% during the 2nd quarter. Wasatch Advisors Inc. now owns 1,018,219 shares of the specialty pharmaceutical company’s stock worth $20,588,000 after acquiring an additional 376,745 shares during the last quarter. 68.95% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Flexion Therapeutics, Inc. (FLXN) Receives Consensus Rating of “Buy” from Brokerages” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.watchlistnews.com/flexion-therapeutics-inc-flxn-receives-consensus-rating-of-buy-from-brokerages/1722574.html.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.